RE:RE:RE:Can someone please repost the Lancet IPF Article.....Yes and this is why the Feb read out of the IPF trials will be so important. It seems that in addition to 4050 alone some patients were given combos of 4050 + either pirfenidone or nantedanib. If what was found in animal studies plays out in humans, there should be a synergistic effect with the 4050 and pirfenidone. Someone told me recently that pirfenidone is losing market share suggesting that Roche should be keen to partner with PLI on 4050 or buy 4050 outright or buy PLI outright. I prefer the first option of course:-)